Literature DB >> 11777487

Quinacrine non-surgical female sterilization in Bangladesh.

S N Bhuiyan1, R Begum.   

Abstract

This study was undertaken to evaluate the efficacy, safety, and acceptability of transcervical applications of quinacrine along with other adjuvants, such as ampicillin and ibuprofen, for sterilization. The cohort consisted of 750 normal women who requested sterilization and volunteered for this method at the family planning clinic of a tertiary hospital and community clinics in Chittagong, Bangladesh. Several different protocols were followed from October 1989 to April 1999. Each woman received one or two insertions of 180 mg or 252 mg quinacrine with or without adjuvants including 55.5 mg ibuprofen or 125 mg ampicillin. Supplementary contraception was given in the form of combined oral contraceptive pills, barrier methods, or injection of depot medroxyprogesterone acetate for 3 months. Details of each protocol are described in the text. The gross pregnancy failure rate for insertion of 180 mg in 590 women was 3.9% compared to 1.9% for the 160 who received 252 mg. There were no serious complications, and side effects were transient. We conclude that quinacrine non-surgical sterilization is a safe, acceptably effective method when two insertions of 252 mg quinacrine with medroxyprogesterone injection as a supplement is used.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11777487     DOI: 10.1016/s0010-7824(01)00263-3

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  2 in total

1.  Expression changes of antioxidant, apoptotic, anti-apoptotic genes and miR-15b-34a-21-98 in over tissue by using erythromycin, quinacrine and tetracycline in non-surgical sterilization.

Authors:  Murat Kara; Onder Yumrutas; Remzi Atilgan; Melike Baspinar; Ekrem Sapmaz; Tuncay Kuloglu
Journal:  Mol Biol Rep       Date:  2014-09-07       Impact factor: 2.316

Review 2.  Update on permanent contraception options for women.

Authors:  Eva Patil; Jeffrey T Jensen
Journal:  Curr Opin Obstet Gynecol       Date:  2015-12       Impact factor: 1.927

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.